Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06710262 · ClinicalTrials.gov registry record
T-TAS® wS Method Comparison
A clinical trial of Von Willebrand Disease (VWD) and Healthy Donors, sponsored by Hikari Dx.
- Completed
- Registry status
- 115
- Enrollment target
- 2
- Study locations
NCT06710262: Completed study of Von Willebrand Disease (VWD) and Healthy Donors, sponsored by Hikari Dx.
NCT06710262 is a study of Von Willebrand Disease (VWD) and Healthy Donors that has completed, run by Hikari Dx. The registered enrollment target is 115 participants, above the 81-participant average among 4 other Von Willebrand Disease (VWD) trials with a reported enrollment target (42% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06710262, a study of Von Willebrand Disease (VWD) and Healthy Donors, has completed, sponsored by Hikari Dx.
- COMPLETED
- Registry status
- 115 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study involves the collection of blood samples and measurement with the T-TAS PL assay to compare the performance of the T-TAS wS instrument to the T-TAS 01 instrument
Primary Outcome
Agreement of PL assay AUC results between the T-TAS wS and T-TAS 01 measurement systems
Conditions Studied
Interventions
- DIAGNOSTIC_TEST T-TAS PL Assay
Study Locations (2)
Florida
- University of Florida Health Jacksonville - Jacksonville
Maryland
- Sinai Hospital of Baltimore - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2024-08-21 |
| Est. Completion | 2025-07-14 |
What the finished NCT06710262 record still lists
NCT06710262 is an observational study that tracks outcomes without assigning an intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, above the 81-participant average among 4 other Von Willebrand Disease (VWD) trials with a reported enrollment target (42% higher).
The record links to 3 conditions, with Von Willebrand Disease (VWD) appearing as the primary indexed condition, and to 1 intervention - of which T-TAS PL Assay is the first listed.
NCT06710262 reports a single indexed study location in Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT06710262 about?
NCT06710262 is a clinical study titled "T-TAS® wS Method Comparison". This study involves the collection of blood samples and measurement with the T-TAS PL assay to compare the performance of the T-TAS wS instrument to the T-TAS 01 instrument
What is the current status of trial NCT06710262?
This trial is currently completed. The enrollment target is 115 participants. The study started on 2024-08-21. Estimated completion is 2025-07-14.
What conditions does trial NCT06710262 study?
This clinical trial studies the following conditions: Von Willebrand Disease (VWD), Healthy Donors, Antiplatelet Therapy.
What interventions are being tested in trial NCT06710262?
The interventions under investigation include: T-TAS PL Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06710262?
This trial is sponsored by Hikari Dx, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06710262 being conducted?
This trial has 2 study locations across Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Willebrand Disease (VWD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
RECRUITING · Phase 3
-
A Study of Bleeding and Treatment in Participants With Von Willebrand Disease
RECRUITING
-
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
RECRUITING · Phase 3
-
A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI